TY - JOUR
T1 - Testing for selection bias and moral hazard in private health insurance
T2 - Evidence from a mixed public-private health system
AU - Afoakwah, Clifford
AU - Byrnes, Joshua
AU - Scuffham, Paul
AU - Nghiem, Son
N1 - Publisher Copyright:
© 2022 The Authors. Health Economics published by John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Separating selection bias from moral hazard in private health insurance (PHI) markets has been a challenging task. We estimate selection bias and moral hazard in Australia's mixed public-private health system, where PHI premiums are community-rated rather than risk-rated. Using longitudinal cohort data, with fine-grained measures for medical services predominantly funded by PHI providers, we find consistent and robust estimates of advantageous selection among hospitalized cardiovascular disease (CVD) patients. Specifically, we show that in addition to their risk-averse attributes, CVD patients who purchase PHI use fewer services that are not covered by PHI providers (e.g., general practitioners and emergency departments) and have fewer comorbidities. Finally, unlike previous studies, we show that ex-post moral hazard exists in the use of specific “in-hospital” medical services such as specialist and physician services, miscellaneous diagnostic procedures, and therapeutic treatments. From the perspective of PHI providers, the annual cost of moral hazard translates to a lower bound estimate of $707 per patient, equivalent to a 3.03% reduction in their annual profits.
AB - Separating selection bias from moral hazard in private health insurance (PHI) markets has been a challenging task. We estimate selection bias and moral hazard in Australia's mixed public-private health system, where PHI premiums are community-rated rather than risk-rated. Using longitudinal cohort data, with fine-grained measures for medical services predominantly funded by PHI providers, we find consistent and robust estimates of advantageous selection among hospitalized cardiovascular disease (CVD) patients. Specifically, we show that in addition to their risk-averse attributes, CVD patients who purchase PHI use fewer services that are not covered by PHI providers (e.g., general practitioners and emergency departments) and have fewer comorbidities. Finally, unlike previous studies, we show that ex-post moral hazard exists in the use of specific “in-hospital” medical services such as specialist and physician services, miscellaneous diagnostic procedures, and therapeutic treatments. From the perspective of PHI providers, the annual cost of moral hazard translates to a lower bound estimate of $707 per patient, equivalent to a 3.03% reduction in their annual profits.
KW - cardiovascular disease
KW - moral hazard
KW - private health insurance
KW - selection bias
UR - http://www.scopus.com/inward/record.url?scp=85137887579&partnerID=8YFLogxK
U2 - 10.1002/hec.4605
DO - 10.1002/hec.4605
M3 - Article
SN - 1057-9230
VL - 32
SP - 3
EP - 24
JO - Health Economics (United Kingdom)
JF - Health Economics (United Kingdom)
IS - 1
ER -